Immune checkpoint blockade therapies have shown clinical promise in a variety of cancers, but how tumor-infiltrating T cells are activated remains unclear. In this study, we explore the functions of PD-L1 on dendritic cells (DCs), which highly express PD-L1. We observe that PD-L1 on DC plays a critical role in limiting T cell responses. Type 1 conventional DCs are essential for PD-L1 blockade and they upregulate PD-L1 upon antigen uptake. Upregulation of PD-L1 on DC is mediated by type II interferon. While DCs are the major antigen presenting cells for cross-presenting tumor antigens to T cells, subsequent PD-L1 upregulation protects them from killing by cytotoxic T lymphocytes, yet dampens the antitumor responses. Blocking PD-L1 in established tumors promotes re-activation of tumor-infiltrating T cells for tumor control. Our study identifies a critical and dynamic role of PD-L1 on DC, which needs to be harnessed for better invigoration of antitumor immune responses.
Antigen presentation is a dynamic event of an effective antitumor immune response1. During this process, antigen-presenting cells (APCs) capture and present tumor antigens to T cells, leading to their priming, activation, and possible reactivation2. Conventional dendritic cells (cDCs) are the most efficient APCs and consist two functional specialized subsets. Type 1 cDC (cDC1) cross-presents tumor antigens to CD8+ T cells3,4. By contrast, type 2 cDC (cDC2) is mainly associated with CD4+ helper T cell responses. Generally, it is believed that DCs play a central role in antitumor immune responses by mediating the priming and activation of T cells5,6,7. Interestingly, DCs might switch from immunostimulatory to immunosuppressive as tumors progress8,9,10. However, the mechanisms mediating such transition remain unclear.
PD-1/PD-L1 blockade therapy emerges as a promising new treatment for cancers in recent years11,12,13,14,15. Antibodies targeting PD-L1 are able to produce durable clinical responses in patients with a variety of cancers. In tumor microenvironment, PD-L1 is highly expressed in tumor cells as well as immune cells, such as DCs, macrophages, myeloid-derived suppressor cells (MDSCs), and Tregs16. However, the relative contributions of PD-L1 on these cells remain incompletely understood. PD-L1 on tumor cells is widely used as a biomarker for checkpoint blockade therapy. Assays measuring PD-L1 expression on tumor cells has been approved by US Food and Drug Administration as a companion diagnostic for PD-1/PD-L1 blockade therapy to determine whether a patient can benefit from the therapy17. However, almost a half of patients positive for tumor PD-L1 do not respond while some patients with PD-L1 negative on tumor cells can still respond to PD-L1 blockade, suggesting that the working model of how PD-1/PD-L1 signaling inhibits immune responses might be more complicated18. We and others have shown that, at least in some tumor models, PD-L1 on immune cells plays a more important role19,20,21,22,23,24,25,26,27. In the current study, we seek to further explore how PD-1/PD-L1 signaling works during host antitumor immune responses. We find that tumor-infiltrating DCs express a high level of PD-L1, which plays a critical role in limiting antitumor immune responses. In mouse model lacking PD-L1 on DCs, the therapeutic effects of PD-L1 blockade completely disappear. PD-L1 on DCs is upregulated during antigen-presentation to protect DCs from cytotoxicity of activated T cells. However, such effect also dampens the antitumor immune responses. These results provide additional insights into the mechanisms of immune checkpoint blockade therapy.
PD-L1 on DCs is essential for checkpoint blockade therapy
PD-L1 expression can be induced in many cells during inflammation responses. Our previous study has shown that blocking PD-L1 on myeloid cells is important for the responses to checkpoint blockade therapy19. To further identify which cell(s) is essential, we profiled PD-L1 expression levels on different cell types in tumor microenvironment by flow cytometry. PD-L1 expression on DCs was higher than other cells (Fig. 1a). In order to define the roles of PD-L1 on DC, we generated PD-L1-conditional knockout mice (Fig. 1b and Supplemental Fig. 1a). The mice were crossed with CD11c-cre to specifically knockout PD-L1 on DC. Flow cytometry data showed that PD-L1 expression was completely absent on DCs (CD11c+MHC II+) but not on other cells (Fig. 1c). Deficiency in PD-L1 does not affect DC development, as similar numbers of cells were found in the spleen and lymph node (LN) of conditional knockout mice (Supplementary Fig. 1b–f). To test the physical contribution of PD-L1 on DC, wild-type (WT) MC38 cells were inoculated into CD11c-cre;Pdl1fl/fl mice. Tumors grew slower in conditional knockout mice comparing to control mice (Fig. 1d). Specifically, tumor sizes were ~600 mm3 in control mice at 29 days after inoculation, while the sizes were ~300 mm3 in DC-conditional PD-L1 knockout mice. There was no difference in PD-L1 expression by tumor cells (Fig. 1e). These data indicate a critical role of PD-L1 on DC for the antitumor immune responses. To measure the spontaneous immune responses against tumor, tissues were isolated from MC38 tumor-bearing mice and analyzed. T cell infiltration slightly increased in conditional knockout mice (Supplementary Fig. 2a). And there was a moderate increase of total CD8+ T cell activation in the absence of PD-L1 on DCs (Supplementary Fig. 2b, c). Next, we sought to evaluate antigen-specific responses. To measure endogenous antitumor immune responses, mice were challenged with OVA-expressing E.G7 cells. OT-1-specific T cells were enumerated by tetramer staining. More OT-1-specific CD8+ T cells were observed in DC-conditional knockout mice (Fig. 1f). To further characterize the functionality of DCs, mice were challenged with MC38 tumor expressing SIY as a model antigen. After tumor established, DCs were isolated from draining LNs (dLNs) and coincubated with naïve 2 C T cells. In the absence of PD-L1, DCs were more potent in priming T cells (Fig. 1g). These data suggest that PD-L1 on DCs plays important roles during T cell activation.
While most clinical trials focus on PD-L1 expression on tumor cells, cellular mechanisms by which PD-L1 suppresses cytotoxic T lymphocyte has not been well-defined due to the lack of confirmatory results. To evaluate the role of PD-L1 on DC for immunotherapy, we treated tumor-bearing conditional knockout mice with IgG or anti-PD-L1 antibody. Strikingly, MC38 tumors grew in DC-conditional PD-L1 knockout mice did not respond to PD-L1 blockade therapy at all (Fig. 2a). Another tumor model, E.G7, failed to respond to anti-PD-L1 as well (Supplementary Fig. 3a). A central role of DCs in T cell activation is their ability to present tumor antigens and to mediate T cell cross-priming3. Conventional DCs consist two functional different populations, cDC1 and cDC2. It has been reported that Batf3-deficient mice fail to generate cDC1s, which are important for antigen cross-presentation. Therefore, we challenged Batf3−/− mice with tumors and treated with anti-PD-L1. Although PD-L1 blockade therapy controlled tumor growth efficiently in WT mice, the same treatment failed to control tumor growth in Batf3−/− mice (Fig. 2b). Consistent with its profound role in CD8+ T cell priming, there was limited number of CD8+ T cell inside tumor microenvironment in Batf3−/− mice (Supplementary Fig. 3b). Collectively, these data suggest a key role of PD-L1 on DCs, likely cDC1s, in the responses to PD-L1 blockade therapy. In addition, DC-mediated antigen cross-presentation is essential for optimal tumor control by checkpoint blockade therapy.
PD-L1 on DCs is upregulated by IFN-γ and T cells in tumor
Since our data suggested that DC is critical for the responses to checkpoint blockade therapy, we measured PD-L1 on cDC1 and cDC2 by flow cytometry (Supplementary Fig. 3c). In naïve mice, cDC1 expressed a low level of PD-L1 in both spleen and LN (Fig. 3a, b). In MC38 tumor-bearing mice, cDC1 significantly upregulated PD-L1 in dLNs (Fig. 3b and Supplementary Fig. 3d). In addition, cDC1 in tumor microenvironment has the highest change in PD-L1 expression. By contrast, most cDC2 expressed a high level of PD-L1, which was further upregulated after tumor challenged (Fig. 3b). Similar results were observed in E.G7 model (Supplementary Fig. 3e). It is well-established that cDC can be generated ex vivo by bone marrow culture protocols with FLT3-L induction28 (Supplementary Fig. 4). FLT3-L-induced bone marrow-derived DCs (BMDCs) expressed a low level of PD-L1 (Fig. 3c). These data suggest that PD-L1 on cDC1 is under dynamic regulations. PD-L1 expression can be upregulated by inflammatory cytokines, especially interferons (IFNs)29. Thus, we investigate whether type I or II IFN signaling is involved in the upregulation of PD-L1 on DCs. In an in vitro system, treatment with both type I and II IFNs dramatically upregulated PD-L1 in BMDCs (Fig. 3d). Similar effects were observed in isolated primary cDCs (Fig. 3e). To evaluate the contributions of IFNs in vivo, type I or II IFN signaling was blocked by neutralizing antibodies. The upregulation of PD-L1 was significantly reduced in the absence of IFN-γ, while blocking type I IFN signaling had limited effects (Fig. 3f). Since CD8+ T cell is critical for antitumor immunity and is one of the major sources of IFN-γ, we wonder whether IFN-γ was produced by CD8+ T cells. As expected, depletion of CD8+ T cells reduced PD-L1 expression to a similar level as blocking IFN-γ (Fig. 3f). To recapitulate these effects in vitro, DCs were cocultured with activated T cells in the presence of neutralizing antibody against IFN-γ. PD-L1 upregulation significantly decreased in the absence of IFN-γ (Fig. 3g). In summary, we found that PD-L1 on cDCs is upregulated by type II IFN and CD8+ T cells upon tumor challenge.
PD-L1 is upregulated upon antigen uptake on type 1 DCs
DCs play a central role for T cell priming. Specifically, cDC1 is the major APCs to carry tumor antigens from tumor tissues to draining LNs for T cell cross-priming30. To visualize antigen uptake in vivo, we inoculated mice with MC38-EGFP cells, which express EGFP as a reporter tumor antigen. Some cDC1s were positive for EGFP in tumor tissues and draining LN (Fig. 4a). By contrast, cDC2s took up antigens in tumor tissues while no/few EGFP-positive cDC2s were observed in dLN. To find out whether there is any relationship between PD-L1 expression and antigen presentation, we measured PD-L1 levels on DC subsets after antigen uptake. Intriguingly, EGFP-positive cDC1s showed the highest level of PD-L1 expression in the draining LN (Fig. 4b). In tumor tissues, we found that EGFP-positive cDC1s showed much higher PD-L1 expression comparing to EGFP-negative cDC1s (Fig. 4c). No significant difference was observed in cDC2s, suggesting that mechanisms regulating PD-L1 expression in these cells might be different. Ex vivo generated BMDCs were able to uptake antigens (Fig. 4d). However, there was less difference in PD-L1 expression after antigen uptake (Fig. 4e). These data suggested that PD-L1 upregulation in DCs was mediated by stimulations from other cells/cytokines in vivo. To identify the key factors, we neutralized type I or type II IFNs by antibody. Interestingly, even though antibody blocking did not affect antigen uptake, PD-L1 on EGFP-positive cDC1s was significantly reduced in the absence of type II IFN (Fig. 4f, g). Depletion of CD8+ T cells showed similar effects (Fig. 4g). By contrast, the reduction of PD-L1 levels was mild in EGFP-negative cDC1s. These data demonstrate that PD-L1 expression on cDC1s is upregulated upon antigen uptake by IFN-γ and T cells.
PD-L1blockade reactivates tumor-infiltrating T cells
PD-L1 blockade can either work by enhancing naïve T cell priming in draining LN, or by reactivating dysfunctional T cells in tumor tissues. To investigate which mechanism(s) is more important, we utilized FTY720 to block T cell infiltration to tumor tissues. FTY720 is a small-molecule analog of sphingosine 1-phosphate (S1P). FTY720 treatment induces the internalization and degradation of S1P receptor, thus prevents lymphocyte egress from the LNs31. PD-L1 blockade therapy did not work if T cell trafficking was blocked in an early phase, such as eight days after tumor inoculation (Fig. 5a). Interestingly, if FTY720 was applied in a later time point when the tumors were more established, blocking T cell infiltration had no significant effects on the therapeutic effects of anti-PD-L1 (Fig. 5b). To validate the effects of FTY720 treatment, we measured T cell levels in peripheral blood and tumor tissues. Majority of the T cells disappeared from the peripheral blood immediately after FTY720 treatment (Supplementary Fig. 5a). The number of tumor-infiltrating T cells reduced as well (Supplementary Fig. 5b). PD-L1 blockade therapy significantly increased the number of activated (IFN-γ+) CD8+ T cells inside tumor (Fig. 5c). When T cell infiltration was inhibited in an early phase, the number of IFN-γ+ T cells dropped significantly. By contrast, there was no difference in IFN-γ+ T cells if FTY720 was applied in a later time point (Fig. 5c). Taken together, these data suggest that antitumor effects mainly depend on newly activated T cells in the LN in early stage tumors. However, as the tumors progress, sufficient T cells stay inside tumor tissues but they become more dysfunctional. And antitumor effects more depend on the reactivation of T cells inside tumors.
Under normal conditions, expression of PD-L1 protects the host from autoimmune diseases by preventing nonspecific activation or killing of the cytotoxic T lymphocytes32. Thus, we wonder what the physical function of PD-L1 on DCs is. We measured DC survival by staining with live/dead dye. Interestingly, the survival of DCs was worse in the absence of PD-L1 (Fig. 5d). One of the functions of IFN-γ is to induce cytotoxicity. It has been proposed that PD-L1 signaling was able to protect tumor cells from such cytopathic effect33. We observed that IFN-γ was able to reduce viabilities of both tumor and dendritic cells (Fig. 5e). However, these effects could not be rescued by blocking PD-L1. As DCs closely contact T cells for antigen presentation, we wonder whether PD-L1 expression could protect them from cytotoxic killing by activated T cells. To recapitulate such killing in vitro, we isolated DCs from conditional knockout mice, loaded with OT-1 peptides, and coincubated them with activated OT-1 T cells. PD-L1-deficient cDC1s and cDC2s were more susceptible to killing by OT-1 T cells (Fig. 5f). The cytotoxicity was contact-dependent as it was abrogated in a transwell assay (Supplementary Fig. 6). Together, these data suggest that DCs upregulate PD-L1 expression to protect themselves from killing by cytotoxic T lymphocytes, which also dampers the antitumor immune responses. Blocking PD-L1 signaling on DC is essential for optimal antitumor immune responses.
The expression of PD-L1 is limited in normal condition. However, it can be upregulated during inflammation in many cells34. Due to the lack of proper animal models, the contributions of PD-L1 on cells other than tumor remains unclear35. Early study has shown that PD-L1 can be detected on patient-derived myeloid DC36. But its function in vivo is yet to be determined. In the current study, we sought to explore these questions by using cDC1-deficient mice and generating DC-conditional PD-L1 knockout mice. We observed that therapeutic effects of PD-L1 blockade therapy are completely disappeared in DC-conditional knockout mice, even though other cells still express high levels of PD-L1. Specifically, cDC1s, which are particularly important for the priming and activation of CD8+ T cells, upregulate PD-L1 expression upon antigen uptake. Consistent with a recent study, we found that PD-L1 on DCs protects them from killing by cytotoxic T lymphocytes, yet dampens the antitumor immune responses37. In addition, PD-L1 upregulation on cDC1s is mediated by IFN-γ produced by activated T cells. Such signaling forms a negative feedback to control T cell (re-)activation. Consistently, lack of cDC1s greatly reduces the number of tumor-infiltrating lymphocytes. Therefore, PD-L1 on cDC1s is likely to prevent the overly expansion of tumor-infiltrating lymphocytes, and to protect the major APCs from killing by activated or reactivated T cells.
Besides PD-1, PD-L1 can also bind to another receptor CD80. An interesting fact is that APCs, including DCs, might express PD-1, PD-L1, and CD80 at the same time38. Furthermore, PD-L1 is able to interact with PD-1 and CD80 in cis, which makes the working model more complicated38,39,40,41,42. In an in vitro system, substantial CD80 expressed on APCs neutralizes PD-L1, thus preventing it from engaging PD-1 to inhibit T cell activation40. However, analysis of patient samples shows that PD-L1 is expressed much more abundantly than CD80 on DCs43. Therefore, it is likely that PD-L1 on DCs works to inhibit T cell activation in most scenarios. Indeed, blocking PD-L1 on human DCs augments their T cell priming ability36,43. However, which type(s) of DCs contributes to these effects has not been clear. Interestingly, by utilizing single-cell sequencing to analyze non-small-cell lung cancer samples, Maier et al. identified a subset of DCs which is enriched in immunoregulatory molecules44. Consistent with our data, they found that PD-L1 on DCs was upregulated after uptaking tumor antigens. However, the DC subset is found to be different from canonical cDCs44. These discrepancies might be results of different cell/tumor models and experimental setups. In our current study, we utilized DC-conditional PD-L1-knockout mouse and tumor models responding to PD-L1 blockade therapy. We identified a critical and dynamical role of PD-L1 on DCs in T cell (re-)activation and immune checkpoint blockade therapy. The functional and mechanistic studies will provide new insights into the mechanisms of checkpoint blockade therapy.
During an effective antitumor immune response, APCs uptake and present tumor antigens to T cells, leading to T cell activation for tumor destruction45. In an established tumor microenvironment, majority of the infiltrating T cells are dysfunctional46. Whether PD-1/PD-L1 blockade therapy works by recruiting newly activated T cells or by reactivating tumor resident T cells is under debate35,47. Conclusions from clinical studies remain controversial48. It has been shown that majority of tumor-specific T cell clones after anti-PD-1 treatment are different from pre-existing tumor-infiltrating T cells in basal or squamous cell carcinoma49. Another study found that a subset of dysfunctional tumor-infiltrating T cells is able to respond to anti-PD-1 therapy efficiently in melanoma patients50. In animal models, it has been shown that T cell priming in LN is essential for checkpoint blockade therapy, as early surgical removal of LN after tumor inoculation eliminates the therapeutic effects51,52. Consistently, we found that preventing newly activated T cells from entering tumor ablates majority of the antitumor effects in early stage tumors. However, inoculation of cultured cancer cells induces massive apoptosis and antigen release in the first few days. This process might result in artificial priming of T cells in the LN53. Therefore, we did the same treatment in late stage tumors, where most of these priming events were gone. We found that majority of the antitumor effects rely on tumor-infiltrating T cells. Our studies provide a potential explanation for the controversial observations in clinic. In these patients with massive tumor cell death (e.g., heavily treated patients) or strong immunogenicity, PD-1/PD-L1 blockade therapy may rely on both newly activated and reactivated T cells. By contrast, in patients with less antigen release or few functional T cells, efficacy of the therapy will more rely on reactivation of the pre-existing T cells. Nevertheless, our study highlights an important role of PD-L1 on DC for the inhibition of T cell (re-)activation, which needs to be harnessed for better invigoration of antitumor immune responses.
Wild-type C57BL/6 mice were purchased from Vital River (Beijing, China). Batf3−/− and CD11c-cre mice were purchased from the Jackson Laboratory. Pdl1fl/fl mice were generated in the animal core. All mice were maintained under specific pathogen-free conditions at 22–26 °C with a 12:12 h dark/light cycle and 40–70% humidity. Wild-type female mice were used at an age of 6–8 weeks. For genetic-modified mice, age and sex matched mice were used for each experiment. Both female and male mice were used at an age of 6–12 weeks.
Cell lines and reagents
MC38, E.G7, B16F10, and 293 T cells were from American Type Culture Collection. Cells were cultured in 5% CO2 and maintained in vitro in DMEM (MC38, B16F10, and 293 T) or RPMI-1640 (E.G7) medium supplemented with 10% fetal bovine serum (FBS), nonessential amino acids, 100 U/ml penicillin, and 100 µg/ml streptomycin. Recombinant murine IFN-α was produced as Fc-fusion protein in 293 T cells and purified by a protein A column.
Generation of MC38-EGFP, MC38-OVA, and MC38-SIY cell lines
In total, 293 T cells were transfected with three plasmids (pSIN-EGFP-puro, psPAX2, and pMD2.G) to produce lentivirus encoding EGFP. Forty-eight hours later, lentivirus was harvested and filtered through 0.45 μm filter. Wild-type MC38 cells were transduced with lentivirus. Two days after transduction, cells were treated with 5 µg/ml puromycin until resistant clones emerged. Single clones of EGFP-expressing MC38 cell (MC38-EGFP) were selected by limiting dilution. EGFP expression was confirmed by flow cytometry. MC38-OVA and MC38-SIY cell lines were generated similarly.
Flow cytometric analysis
Cells were blocked with anti-CD16/32 (clone 2.4G2) for 20 min at room temperature. Then cells were incubated with antibodies for 30 min. After washed, samples were acquired on a CytoFLEX S (Beckman Coulter) flow cytometer with CytExpert software (Beckman Coulter). Data were analyzed by FlowJo software (TreeStar).
Tumor growth and treatments
MC38 or E.G7 cells were subcutaneously injected into the right flank of the mice. When tumors reached certain size, mice were randomized to groups and treated intraperitoneally (i.p.) with IgG or anti-PD-L1 on indicated days. Tumor volumes were measured twice weekly and calculated as (Length × Width × Height/2). To inhibit lymphocyte trafficking, mice were treated i.v. with 50 μg FTY720 on day 8 or 14 after tumor inoculation. After first injection, ten micrograms FTY720 were given i.v. every day to maintain inhibition. For antibody blocking experiments, mice were treated with 200 μg IgG, 100 μg anti-IFNAR1, 200 μg anti-IFN-γ, or 200 μg anti-CD8 i.p. on day 0, 3, 7, and 11. Tissues were collected and analyzed on day 14.
Cell isolation from tissues
Tissues were cut into small pieces before digested in RPMI-1640 medium with 1 mg/ml type IV collagenase and 100 μg/ml DNase I. After digestion, tissues were passed through a 70 μm cell strainer to make single cell suspensions.
T cell stimulation in vitro
Splenic CD8+ T cells were isolated with EasySep Mouse CD8+ T cell Isolation Kit and stimulated with 5 μg/ml anti-CD3 (coated on plate) and 2 μg/ml anti-CD28 (soluble) according to standard protocol. Forty-eight hours after stimulation, T cells were harvested for functional assays. DCs were purified by FACS or EasySep Mouse CD11c Positive Selection Kit II according to the manufacturer’s instruction. DCs and activated T cells were cocultured for 24 h with or without 10 μg/ml anti-IFN-γ. PD-L1 levels on DCs were measured by flow cytometry.
In vitro T cell killing assay
Purified OT-1 T cells were activated by anti-CD3 and anti-CD28 for 48 h. Purified DCs were loaded with 5 μg/ml OT-1 peptides for 30 min at 37 °C. After washed, DCs were coincubated with activated OT-1 T cells for 4 h at an E:T ratio of 3. Cell death were measured by flow cytometry.
Enzyme-linked immunosorbent spot assay (ELISPOT)
Spleen or draining LN were isolated from MC38 tumor-bearing mice. Single cell suspensions were prepared. Cells (4 × 105) were cultured for 24 h. In T cell priming assay, purified DCs (1 × 104) from LN of MC38-SIY tumor-bearing mice were cocultured with naïve T cells (1 × 105) purified from 2 C mice with or without 5 μg/ml SIY peptides for 48 h. ELISPOT assay was performed using an IFN-γ ELISPOT assay kit (BD Biosciences) according to manufacturer’s instruction. Spots were enumerated by ImmunoSpot Analyzer (CTL).
in vitro culture of BMDCs or primary DCs
Bone marrow cells were obtained from WT mice. Cells were cultured at 10 cm Petri dishes in RPMI-1640 medium containing 10% FBS and 55 µmol/L 2-Mercaptoethanol. FLT3-L (150 ng/ml) were added every 3 days. BMDCs were harvested on day 9 and cocultured with irradiated MC38-EGFP cells at a ratio of 3:1 for 24 h. EGFP signal was measured by flow cytometry. In IFN-stimulation assays, BMDCs or purified DCs were treated with 500 ng/ml IFN-α or 950 ng/ml IFN-γ for 24 h. The concentrations of IFNs were chosen so that they induced similar levels of PD-L1 in MC38 cells. PD-L1 levels were measured by flow cytometry.
Cells were seeded in 96 well plates and treated with 10 ng/ml murine IFN-γ (and 10 μg/ml anti-PD-L1) for 96 h33. MTT assays were performed following manufacturer’s instructions. Briefly, cells were incubated in 0.5 mg/ml MTT for 5 h at 37 °C. MTT crystals were dissolved in 150 μl DMSO and absorbance was measured in a plate reader at 570 nm. Cell viability was normalized to mock treated cells.
Data are shown as mean ± SEM. Differences between two groups were compared by an unpaired Student’s two-tailed t test. Tumor growth curves were assessed by two-way ANOVA with Turkey’s testing for multiple comparisons. A p value < 0.05 was considered statistically significant. Statistical analysis was performed using the GraphPad Prism software (GraphPad). Tumor sizes were recorded and calculated by Excel (Microsoft). DNA gel images were acquired by Image Lab (Bio-Rad).
Animal experiment protocols were consistent with guidelines of the Laboratory Animal Research Center of Tsinghua University. The laboratory animal facility has been accredited by Association for Assessment and Accreditation of Laboratory Animal Care International. All animal studies were approved by the Animal Care and Use Committee of Tsinghua University.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The data supporting the findings of this study are available within the article and its Supplementary Information files and from the corresponding authors on reasonable request. The source data underlying Figs. 1a, d–g, 2a, b, 3b–g, 4a, c–g, 5a–f, and Supplementary Figs. 1a–f, 2a–c, 3a, b, d, e, 5a, b, and 6 are provided as a Source Data file.
Chen, DanielS. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Gardner, A. & Ruffell, B. Dendritic cells and cancer immunity. Trends Immunol. 37, 855–865 (2016).
Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).
Durai, V. & Murphy, KennethM. Functions of murine dendritic cells. Immunity 45, 719–736 (2016).
Spranger, S., Bao, R. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
Salmon, H. et al. Expansion and activation of CD103+ dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924–938 (2016).
Roberts, E. W. et al. Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324–336 (2016).
Scarlett, U. K. et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J. Exp. Med. 209, 495–506 (2012).
Norian, L. A. et al. Tumor-infiltrating regulatory dendritic cells inhibit CD8 T cell function via L-arginine metabolism. Cancer Res. 69, 3086 (2009).
Strauss, L. et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Science. Immunology 5, eaay1863 (2020).
Brahmer, J. R. et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563–567 (2014).
Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3 — potential mechanisms of action. Nat. Rev. Immunol. 15, 45–56 (2014).
Garber, K. Predictive biomarkers for checkpoints, first tests approved. Nat. Biotechnol. 33, 1217–1218 (2015).
Sunshine, J. & Taube, J. M. PD-1/PD-L1 inhibitors. Curr. Opin. Pharmacol. 23, 32–38 (2015).
Tang, H. et al. PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression. J. Clin. Invest. 128, 580–588 (2018).
Kleinovink, J. W. et al. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. OncoImmunology 6, e1294299 (2017).
Lau, J. et al. Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice. Nat. Commun. 8, 14572 (2017).
Juneja, V. R. et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J. Exp. Med. 214, 895–904 (2017).
Noguchi, T. et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol. Res. 5, 106–117 (2017).
Rashidian, M. et al. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proc. Natl Acad. Sci. USA 116, 16971–16980 (2019).
Antonios, J. P. et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 19, 796–807 (2017).
Zhang, X. et al. Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells. Cell. Mol. Immunol. 16, 392–400 (2019).
Lin, H. et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression. J. Clin. Invest. 128, 805–815 (2018).
Mayer, C. T. et al. Selective and efficient generation of functional Batf3-dependent CD103+ dendritic cells from mouse bone marrow. Blood 124, 3081–3091 (2014).
Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434–452 (2018).
Eisenbarth, S. C. Dendritic cell subsets in T cell programming: location dictates function. Nat. Rev. Immunol. 19, 89–103 (2019).
Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29, 285–296 (2016).
Nishimura, H. et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319–322 (2001).
Gato-Cañas, M. et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell Rep. 20, 1818–1829 (2017).
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).
Munn, D. H. The host protecting the tumor from the host — targeting PD‑L1 expressed by host cells. J. Clin. Invest. 128, 570–572 (2018).
Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity. Nat. Med. 9, 562–567 (2003).
Chen, L. et al. B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc. Natl Acad. Sci. USA 115, 3126–3131 (2018).
Zhao, Y. et al. Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells. Cell Rep. 24, 379–390.e6 (2018).
Chaudhri, A. et al. PD-L1 binds to B7-1 only In Cis on the same cell surface.Cancer Immunol. Res. 6, 921–929 (2018).
Sugiura, D. et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science 364, 558–566 (2019).
Zhao, Y. et al. PD-L1:CD80 Cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity 51, 1059–1073.e9 (2019).
Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681–691 (2020).
Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12, eaav7431 (2020).
Maier, B. et al. A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580, 257–262 (2020).
Ruhland, M. K. et al. Visualizing synaptic transfer of tumor antigens among dendritic cells. Cancer Cell 37, 786–799.e5 (2020).
Crespo, J., Sun, H., Welling, T. H., Tian, Z. & Zou, W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr. Opin. Immunol. 25, 214–221 (2013).
Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).
Callahan, M. K. & Wolchok, J. D. Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes? Cancer Cell 36, 215–217 (2019).
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).
Chamoto, K. et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc. Natl Acad. Sci. USA 114, E761–70 (2017).
Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight 3, e124507 (2018).
Zheng, W. et al. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget 7, 43039–43051 (2016).
We thank Dr. Wenxin Zheng for helpful scientific discussions. We thank services provided by the Laboratory Animal Research Center and Flow Cytometry Facility of Tsinghua University. This study was supported by Tsinghua-Peking University Center for Life Sciences (045-61020100119), Start-up Foundation of Tsinghua University (53332201119), and Foshan-Tsinghua Innovation Special Fund (FTISF, 041522068) to H.T.
The authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewers for contribution to the peer review of this work. Peer review reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Peng, Q., Qiu, X., Zhang, Z. et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade. Nat Commun 11, 4835 (2020). https://doi.org/10.1038/s41467-020-18570-x
This article is cited by
Nature Communications (2023)
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
Molecular Cancer (2022)
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors
Journal of Hematology & Oncology (2022)
AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC
Translational Medicine Communications (2022)
Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies
Cell Communication and Signaling (2022)